Response to Antiangiogenic Therapy Is Associated with <i>AIMP</i> Protein Family Expression in Glioblastoma and Lower-Grade Gliomas
This study identifies AIMP2 as a novel biomarker predictive of antiangiogenic treatment response in recurrent GBM. Through multiomic and single-cell analyses, AIMP2 is shown to be upregulated in aggressive gliomas and linked to angiogenesis. Its expression and methylation status offer a clinically applicable stratification tool, enabling more personalized therapeutic approaches and improved outcomes in patients receiving antiangiogenic therapies.
Authors
- Humaira Noor (ORCID: https://orcid.org/0000-0001-8887-8122)
- Haruka Itakura (ORCID: https://orcid.org/0000-0003-4382-0183)
- Olivier Gevaert (ORCID: https://orcid.org/0000-0002-9965-5466)
- Yuanning Zheng (ORCID: https://orcid.org/0000-0002-0018-3252)
Institutions
- Palo Alto University (US)
- Stanford Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0170
- Citations
- 1
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- National Institutes of Health
- National Cancer Institute